Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction

References

• AntmanEMAnbeDTArmstrongPWACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With A Myocardial Infarction)Circulation200411058863615289388
   PubMed Web of Science ®Google Scholar
• AsanoKDutcherDLPortJDSelective downregulation of the angiotensin II AT1-receptor subtype in the failing human ventricular myocardiumCirculation20069511932009054849
   PubMedGoogle Scholar
• ChioleroABurnierMPharmacology of valsartan, an angiotensin II receptor antagonistExpert Opin Investig Drugs20067191525
   Google Scholar
• CohnJNTognoniGA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med200134516677511759645
   PubMed Web of Science ®Google Scholar
• ColucciWSAntmanEMPathophysiologic and clinical considerations in the treatment of heart failure: An overviewCardiovascular Therapeutics20062PhiladelphiaW.B.Saunders Company293324
   Google Scholar
• DicksteinKKjekshusJAnd the OPTIMAAL Steering CommitteeEffects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomised trialLancet20023607526012241832
   PubMed Web of Science ®Google Scholar
• DzauVJTissue renin-angiotensin system in myocardial hypertrophy and failureArch Intern Med1993153937428386920
   PubMed Web of Science ®Google Scholar
• GoodfriendTLElliottMECattKJAngiotensin receptors and their antagonistsN Engl J Med19963341649548628362
   PubMed Web of Science ®Google Scholar
• HayashidaWvan EyllCRousseauMFRegional remodeling and nonuniform changes in diastolic function in patients with left ventricular dysfunction:modification by long-term enalapril treatmentJ Am Coll Cardiol1993221403108227798
   PubMed Web of Science ®Google Scholar
• HaywoodGAGullestadLKatsuyaTAT1 and AT2 angiotensin receptor gene expression in human heart failureCirculation199795120169054850
   PubMed Web of Science ®Google Scholar
• HoriuchiMAkishitaMDzauVJRecent progress in angiotensin II type 2 receptor research in the cardiovascular systemHypertension1999336132110024316
   PubMed Web of Science ®Google Scholar
• HuntSABakerDWChinMHACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult:executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)J Am Coll Cardiol20013821011311738322
   PubMed Web of Science ®Google Scholar
• LatiniRMassonSAnandIEffects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure:the Valsartan Heart Failure Trial (Val-HeFT)Circulation20021062454812417542
   PubMed Web of Science ®Google Scholar
• MaggioniAPAnandIGottliebSOEffects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitorsJ Am Coll Cardiol20024014142112392830
   PubMed Web of Science ®Google Scholar
• MankadSD’AmatoTAReichekNCombined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodelingCirculation200110328455011401943
   PubMed Web of Science ®Google Scholar
• McMurrayJJPfefferMASwedbergKWhich inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?Circulation20041103281815545527
   PubMed Web of Science ®Google Scholar
• McMurrayJJVOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:the CHARM-Added trialLancet20033627677113678869
   PubMed Web of Science ®Google Scholar
• MenardJCampbellDJAziziMSynergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight and renin in spontaneously hypertensive ratsCirculation199796307289386177
   PubMed Web of Science ®Google Scholar
• MitchellGFLamasGAVaughanDELeft ventricular remodeling in the year following first anterior myocardial infarction:a quantitative analysis of contractile segment length and ventricular shapeJ Am Coll Cardiol1992191136441532970
   PubMed Web of Science ®Google Scholar
• PfefferMAACE inhibition in acute myocardial infarction [editorial]N Engl J Med1995332118207990887
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJLeizoroviczAValsartan in Acute Myocardial Infarction trial (VALIANT):rationale and designAm Heart J20001407275011054617
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [Erratum in N Engl J Med, 2004. 350:203]N Engl J Med2003349189390614610160
   PubMed Web of Science ®Google Scholar
• RutherfordJDPfefferMAMoyeLAEffects of captopril on ischaemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. SAVE investigatorsCirculation199490173187923656
   PubMed Web of Science ®Google Scholar
• SioufiAMarfilFJaouenAThe effect of age on the pharmacokinetics of valsartanBiopharm Drug Dispos199819237449604123
   PubMed Web of Science ®Google Scholar
• SpinaleFGde GasparoMWhitebreadSModulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. I. Effects on left ventricular performance and neurohormonal systemsCirculation1997962385969337215
   PubMed Web of Science ®Google Scholar
• SpinaleFGMukherjeeRIanniniJPModulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. II. Effects on myocyte contractile processesCirculation19979623974069337216
   PubMed Web of Science ®Google Scholar
• WhiteHDAylwardPEGHuangZMortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both following acute myocardial infarction:results from the Valsartan In Acute Myocardial Infarction (VALIANT) trialCirculation20051123391916301343
   PubMedGoogle Scholar
• ZismanLSAsanoKDutcherDLDifferential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heartCirculation1998981741
   Web of Science ®Google Scholar